<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title>8-K</title>
</head>
<body bgcolor="white">
<p style=
"line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">
&nbsp;</p>
<p style=
"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">
&nbsp;</p>
<p style=
"margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"
align="center"><b>UNITED STATES</b></p>
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"
align="center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"
align="center"><b>WASHINGTON, D.C. 20549</b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<center>
<p style=
"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">
&nbsp;</p>
</center>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"
align="center"><b>FORM 8-K</b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<center>
<p style=
"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">
&nbsp;</p>
</center>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"
align="center"><b>CURRENT REPORT</b></p>
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"
align="center"><b>Pursuantto Section&nbsp;13 or 15(d)</b></p>
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"
align="center"><b>of the Securities Exchange Act of 1934</b></p>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"
align="center"><b>Date of Report (Date of earliest event reported):
May&nbsp;22, 2018</b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<center>
<p style=
"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">
&nbsp;</p>
</center>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman"
align="center"><b>CYTOMX THERAPEUTICS, INC.</b></p>
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"
align="center"><b>(Exact name of Registrant as Specified in Its
Charter)</b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<center>
<p style=
"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">
&nbsp;</p>
</center>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" width="100%" border="0"
style=
"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt"
align="center">
<tr>
<td width="34%"></td>
<td valign="bottom"></td>
<td width="32%"></td>
<td valign="bottom" width="1%"></td>
<td width="32%"></td>
</tr>
<tr style=
"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top" align="center"><b>Delaware</b></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center"><b>001-37587</b></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center"><b>27-3521219</b></td>
</tr>
<tr style=
"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td valign="top" align="center">
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"
align="center"><b>(State or Other Jurisdiction</b></p>
<p style=
"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"
align="center"><b>of Incorporation)</b></p>
</td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center">
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"
align="center"><b>(Commission</b></p>
<p style=
"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"
align="center"><b>File Number)</b></p>
</td>
<td valign="bottom">&nbsp;</td>
<td valign="top" align="center">
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"
align="center"><b>(IRS Employer</b></p>
<p style=
"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"
align="center"><b>Identification No.)</b></p>
</td>
</tr>
</table>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"
align="center"><b>151 Oyster Point Blvd.</b></p>
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"
align="center"><b>Suite 400</b></p>
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"
align="center"><b>South SanFrancisco, CA 94080</b></p>
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"
align="center"><b>(Address of principal executive offices,
including Zip Code)</b></p>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"
align="center"><b>Registrant’s telephone number, including area
code: (650)&nbsp;515-3185</b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<center>
<p style=
"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">
&nbsp;</p>
</center>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of thefollowing provisions (see General Instructions A.2.
below):</p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<table style=
"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt"
border="0" cellpadding="0" cellspacing="0" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%" valign="top" align="left">☐</td>
<td align="left" valign="top">Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)</td>
</tr>
</table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<table style=
"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt"
border="0" cellpadding="0" cellspacing="0" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%" valign="top" align="left">☐</td>
<td align="left" valign="top">Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)</td>
</tr>
</table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<table style=
"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt"
border="0" cellpadding="0" cellspacing="0" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%" valign="top" align="left">☐</td>
<td align="left" valign="top">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</td>
</tr>
</table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<table style=
"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt"
border="0" cellpadding="0" cellspacing="0" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%" valign="top" align="left">☐</td>
<td align="left" valign="top">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</td>
</tr>
</table>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of thischapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).</p>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;☒</p>
<p style=
"margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any newor revised financial accounting standards
provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&nbsp;&nbsp;☒</p>
<p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<p style=
"line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">
&nbsp;</p>
<p style=
"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">
&nbsp;</p>
<p style='page-break-before:always'></p>
<hr size="3" style="COLOR:#999999" width="100%" align="center" />
<table style=
"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt"
border="0" cellpadding="0" cellspacing="0" width="100%">
<tr style="page-break-inside:avoid">
<td width="9%" valign="top" align="left"><b>Item&nbsp;8.01</b></td>
<td align="left" valign="top"><b>Other Events</b></td>
</tr>
</table>
<p style=
"margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CytomX Therapeutics, Inc., a Delaware corporation (the “Company”),
todayannounced that the U.S. Food and Drug Administration has
cleared the Investigational New Drug (“IND”) application for
CX-2029, a first-in-class CD71-directed Probody™ drug conjugate
being co-developed by the Company and its partnerAbbVie Ireland
Unlimited Company (“AbbVie”). The achievement of this milestone
triggers a $25 million payment to the Company from AbbVie pursuant
to the Company’s CD71 Co-Development and Licensing Agreement
entered into with AbbVie inApril 2016.</p>
<p style='page-break-before:always'></p>
<hr size="3" style="COLOR:#999999" width="100%" align="center" />
<p style=
"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<b>SIGNATURES</b></p>
<p style=
"margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on itsbehalf by the undersigned hereunto duly
authorized.</p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" width="100%" border="0"
style=
"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">
<tr>
<td width="46%"></td>
<td valign="bottom" width="1%"></td>
<td width="4%"></td>
<td valign="bottom"></td>
<td width="2%"></td>
<td valign="bottom" width="1%"></td>
<td width="45%"></td>
</tr>
<tr style=
"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top">Date: May&nbsp;22, 2018</td>
<td valign="bottom">&nbsp;</td>
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="top" colspan="3"><b>CYTOMX THERAPEUTICS, INC.</b></td>
</tr>
<tr style="font-size:1pt">
<td height="16"></td>
<td height="16" colspan="2"></td>
<td height="16" colspan="2"></td>
<td height="16" colspan="2"></td>
</tr>
<tr style=
"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="top">By:</td>
<td valign="bottom" style="BORDER-BOTTOM:1px solid #000000">
&nbsp;</td>
<td valign="top" style="BORDER-BOTTOM:1px solid #000000">/s/
Debanjan Ray</td>
</tr>
<tr style=
"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="top">Debanjan Ray</td>
</tr>
<tr style=
"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom"></td>
<td valign="bottom">&nbsp;</td>
<td valign="top"></td>
<td valign="bottom">&nbsp;</td>
<td valign="bottom">Chief Financial Officer</td>
</tr>
</table>
</body>
</html>

